Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KHK | P50053 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30466800 | 1.00 | AR (0.53) | ARATMNPSR1MAPTPRMT5 | |
| SCHEMBL10222520 | 0.81 | ATM (0.52) | ARATMNPSR1PRMT5PARP1 | |
| SCHEMBL25141598 | 0.79 | PRMT5 (0.40) | ARMAPTPRMT5PARP1SMN1; SMN2 | |
| SCHEMBL29426552 | 0.78 | PRMT5 (0.43) | ARMAPTPRMT5SMN1; SMN2ALDH1A1 | |
| SCHEMBL29426626 | 0.78 | PRMT5 (0.46) | ARPRMT5ALDH1A1 | |
| SCHEMBL23526315 | 0.78 | PRMT5 (0.46) | ARPRMT5ALDH1A1 | |
| SCHEMBL29868197 | 0.76 | KDM4E (0.52) | NPSR1MAPTKDM4EALDH1A1GAA | |
| SCHEMBL4751136 | 0.76 | KDM4E (0.52) | NPSR1MAPTKDM4EALDH1A1GAA | |
| SCHEMBL4134456 | 0.74 | PIK3CA (0.47) | MAPTPRMT5POLBLMNAKDM4E | |
| SCHEMBL30603062 | 0.74 | NPSR1 (0.67) | ATMNPSR1MAPTPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | disclosed |
| EP-4452265-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118507-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2023-06-29 | — | — | WO | disclosed |
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2504317-A1 | POTASSIUM CHANNEL MODULATORS | Abbott Laboratories (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011066168-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | AR 777/4885ATM 1878/4885NPSR1 1214/4885 |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNQ3 | AR 2066/4885ATM 3548/4885NPSR1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.